BioCentury
ARTICLE | Company News

Dong-A ST, Tobira deal

April 25, 2016 7:00 AM UTC

Dong-A granted Tobira exclusive rights to develop and commercialize evogliptin as a single agent or in combination with Tobira’s cenicriviroc in the U.S., Canada, Europe and Australia. Dong-A received $1.5 million up front and is eligible for up to $25 million in development and regulatory milestones for the first indication and up to $10 million for additional indications. The company is also eligible for up to $35 million in commercial milestones, plus tiered royalties. Both companies plan to develop the combination to treat non-alcoholic steatohepatitis (NASH), and Tobira will begin a Phase I trial for the indication later this year. ...